CN103893325B - The application of Herba Hedyotidis Diffusae - Google Patents
The application of Herba Hedyotidis Diffusae Download PDFInfo
- Publication number
- CN103893325B CN103893325B CN201410155195.7A CN201410155195A CN103893325B CN 103893325 B CN103893325 B CN 103893325B CN 201410155195 A CN201410155195 A CN 201410155195A CN 103893325 B CN103893325 B CN 103893325B
- Authority
- CN
- China
- Prior art keywords
- hedyotidis diffusae
- herba hedyotidis
- application
- subarachnoid hemorrhage
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims abstract description 69
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 210000004556 brain Anatomy 0.000 claims description 21
- 238000007917 intracranial administration Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 3
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010042434 Sudden death Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 21
- 210000002330 subarachnoid space Anatomy 0.000 abstract description 11
- 206010048962 Brain oedema Diseases 0.000 abstract description 9
- 208000006752 brain edema Diseases 0.000 abstract description 9
- 206010047163 Vasospasm Diseases 0.000 abstract description 8
- 230000002490 cerebral effect Effects 0.000 abstract description 8
- 230000008499 blood brain barrier function Effects 0.000 abstract description 7
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 31
- 231100000614 poison Toxicity 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 239000003440 toxic substance Substances 0.000 description 11
- 210000004004 carotid artery internal Anatomy 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 10
- 229940126680 traditional chinese medicines Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 210000001841 basilar artery Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 208000001286 intracranial vasospasm Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000002403 Encephalocele Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001528553 Malus asiatica Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000002551 anterior cerebral artery Anatomy 0.000 description 2
- 210000000576 arachnoid Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- ZQBMUHABRSEAIK-UXBLZVDNSA-N 1-[4-[(e)-3-phenylprop-2-enyl]piperazin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCN1C\C=C\C1=CC=CC=C1 ZQBMUHABRSEAIK-UXBLZVDNSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000270955 Achnatherum calamagrostis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 240000007163 Livistona chinensis Species 0.000 description 1
- 240000003146 Lobelia chinensis Species 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 101100108055 Rattus norvegicus Acsm3 gene Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229950006142 carbazochrome salicylate Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229960004817 etamsylate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- CELKBRMLNUNCIP-HTFHIHPASA-M sodium;2-hydroxybenzoate;[(e)-(3-hydroxy-1-methyl-6-oxo-2,3-dihydroindol-5-ylidene)amino]urea Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.NC(=O)N\N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 CELKBRMLNUNCIP-HTFHIHPASA-M 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- -1 stable Chemical compound 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses the application of Chinese medicine Herba Hedyotidis Diffusae, this application is the application of Herba Hedyotidis Diffusae as preparation treatment subarachnoid hemorrhage medicine.By animal model experiment, the present invention confirms that Herba Hedyotidis Diffusae can alleviate the degree of cerebral edema that subarachnoid hemorrhage causes; Promote the absorption of subarachnoid space remained blood; Reduce the destructiveness of blood brain barrier; Alleviate basilar artary vasospasm degree; Improve Neuroscore etc.By improving above-mentioned several clinical indices and then shielding to cerebral tissue, subarachnoid hemorrhage is had significant therapeutic effect.
Description
Technical field
The present invention relates to medical art, specifically a kind of Herba Hedyotidis Diffusae is as the application of preparation treatment subarachnoid hemorrhage medicine.
Background technology
Herba Hedyotidis Diffusae is the herb of Maguireothamnus speciosus Herba Hedyotidis Diffusae, begin to be loaded in " Mingyi Bielu ", another name Herba Hedyotidis Diffusae, Serpentis needle grass, short foot spend Chinese Lobelia, Herba Turczaninowiae Fastigiatae, Radix Picriae felterrae, crane SHECAO, Herba Otteliae Alismoidis etc. in vain, it is the medical material kind that version " Chinese Pharmacopoeia " annex III in 2010 records, record in local medical material standard, be China's conventional Chinese crude drug among the people more before.It is cold in nature, bitter in the mouth, sweet, GUIXIN, liver, spleen channel, pharmacological research show this medicine have antitumor, antiinflammatory, antibacterial, strengthen the effect of immunologic function, there is effect of heat-clearing and toxic substances removing, inducing diuresis to remove edema, for acute appendicitis, furuncle toxic swelling, laryngopharynx swelling and pain, venom, damp and hot yellow cellulitis, nephritis, liver cirrhosis, early stage lymphoid tuberculosis, stomatitis, dysuria etc., having inhibitory action to pathogenic bacterium such as bacillus pyocyaneus, staphylococcus aureus, streptococcus pneumoniae, dysentery bacteriums, is the good medicine of " heat-clearing and toxic substances removing ".At present also for prevention and the auxiliary treatment of various cancer.
The BAIHUASHESHECAO ZHUSHEYE kind of current commercially available SFDA approval is as shown in table 1, and package insert is set forth its function and cured mainly and comprise: heat-clearing and toxic substances removing, inducing diuresis and reducing edema.Respiratory tract infection caused by poison, tonsillitis, pneumonia, cholecystitis, appendicitis, carbuncle furuncle abscess and post-operative infection is accumulate for damp and hot.Also can be used for the auxiliary treatment of cancer.Especially gastric cancer, the esophageal carcinoma, lymphatic cancer, breast carcinoma etc. are widely used.
And the medicine of other preparation of Herba Hedyotidis Diffusae is as shown in table 2, be the preparation containing Herba Hedyotidis Diffusae recorded in version " Chinese Pharmacopoeia " for 2010, totally ten kinds, its effect as described in table, there are no the report for the treatment of subarachnoid hemorrhage.
The BAIHUASHESHECAO ZHUSHEYE kind that table 1 SFDA ratifies
| Authentication code | Approved date | Manufacturer |
| The accurate word 234020595 of traditional Chinese medicines | 2002-10-16 | Area, Fengyang County, Anhui Science Court pharmaceutcal corporation, Ltd |
| The accurate word 234020606 of traditional Chinese medicines | 2002-10-16 | The large east Pharmaceutical Co., Ltd in Anhui |
| The accurate word 222024750 of traditional Chinese medicines | 2002-09-13 | Jilin Longtai Pharmaceutical Co., Ltd. |
| The accurate word 222025029 of traditional Chinese medicines | 2002-09-13 | Xiuzheng Pharmaceutical Group Changchun Gaoxin Pharmaceutical Co., Ltd. |
| The accurate word 222024489 of traditional Chinese medicines | 2002-09-13 | Jilin Province Huinan Changlong Biochemistry Medicine Co., Ltd |
| The accurate word 222022101 of traditional Chinese medicines | 2002-08-16 | Jilin Province Tonghua Zhenguo Medicine Co., Ltd |
| The accurate word 222020807 of traditional Chinese medicines | 2002-08-16 | Jilin Province Huinan Huifa Pharmacy stock Co., Ltd |
| The accurate word 236020632 of traditional Chinese medicines | 2002-06-21 | Yujiang Pharmaceutical Factory |
The preparation containing Herba Hedyotidis Diffusae is recorded in table 2 2010 version " Chinese Pharmacopoeia "
| Preparation title | Record the page number | Preparation effect |
| Yiganning granules | 403 | Air making-up and spleen enlivening, invigorating blood circulation dysentery, heat-clearing and toxic substances removing |
| Twin-arc twin-wire | 610 | Clearing away heat-damp and promoting diuresis, reduce phlegm alleviating distention in middle-JIAO, vital energy regualting and blood circulation-promoting |
| HUAHONG PIAN | 734 | Heat-clearing and toxic substances removing, dampness leukorrhagia stopping, tired pain relieving of dispelling |
| HUAHONG KELI | 735 | Heat-clearing and toxic substances removing, dampness leukorrhagia stopping, tired pain relieving of dispelling |
| Capsule with pseudo-ginseng and Chinese fanpalm seed | 831 | Heat-clearing and toxic substances removing, reducing swelling and alleviating pain, QI invigorating is reduced phlegm |
| The luxuriant GANFU KELI of mattress | 870 | Heat-clearing and toxic substances removing, dampness removing, soothing liver-QI spleen reinforcing |
| Compound Japanese polygala granule | 909 | Relieving sore-throat by clearing away heat, removing obstruction for relieving pain, expelling phlegm for arresting cough |
| Support positive removing food stagnancy capsule | 945 | Spleen invigorating benefit. kidney, change tired removing toxic substances |
| BIYANLING PIAN | 1208 | Removing toxic substances and promoting subsidence of swelling, supplementing QI and nourishing YIN |
| The clear sheet of skin ulcer | 1227 | Heat-clearing and toxic substances removing, reducing heat in the blood and treating stranguria |
Subarachnoid hemorrhage (SAH) is one of modal emergency case of department of neurology, it is bottom brain caused by Different types of etiopathogenises or brain and the spinal cord vascular surface acute hemorrhagic cerebrovascular diseases of breaking, blood flows directly into subarachnoid space, also known as constitutional or spontaneous subarachnoid hemorrhage.After angiorrhexis blood flows into cranial arachnoid cavity of resorption, cranial cavity content increases, and pressure increases, and can cause a series of complication, as hemorrhage, cerebral vasospasm, cerebral edema again, some patients can have epilepsy, upper digestive tract acute gastric mucosa lesious, pulmonary edema etc.Hemorrhage, cerebral vasospasm, cerebral edema are complication serious after SAH again, are also the main causes that patient SAH is lethal, disable.Therefore remedy measures should should be taked early before these complication occur.The clinical a series for the treatment of means this disease having been formed to standardization diagnosis and treatment at present.But the prognosis of this kind of disease is still undesirable, dead residual rate is up to 45%.A nearest research display, the Patients with Subarachnoid Hemorrhage case fatality rate that emergency treatment is admitted to hospital is 33%.Another studies display, all Patients with Subarachnoid Hemorrhage 30 days case fatality rate 45%, mainly death in the 1st day after morbidity.
The clinical Therapeutic Method of current subarachnoid hemorrhage comprises the following aspects:
1. general treatment: answer hospitalization and monitoring; strict bed rest 4 ~ 6 weeks; head is slightly raised; keep quiet, the comfortable and half-light in ward; avoid that patient is excited, firmly defecation or acutely cough; give calmness; analgesic drug product is as bucinnazine, stable, phenobarbital etc.; available laxative and just softening agent keep free movement of the bowels; blood pressure lowering, keeps blood pressure stabilization level before normal or onset, reduction of patient headache and nervous, exciting emotion; after morbidity, a few hours planted agent carries out cardiac monitoring, monitoring vital sign.The patient of long lasting coma, indwelling catheter, notes nutritional support, prevents complication.
2. the treatment of cranium pressure is fallen: subarachnoid hemorrhage can cause cerebral edema and intracranial pressure to raise, there is cerebral hernia in severe patient, actively should carry out dehydration and fall the treatment of cranium pressure, alone or the conbined usage according to the state of an illness, the medicine dehydration poor effect such as available 20% mannitol, furosemide (furosemide), 20% human albumin and have cerebral hernia may time, feasible subtemporal decompression and ventricular drainage, to save patient vitals.
3. prevention is hemorrhage again: suppress plasminogen to be formed with antifibrinolytics, postpone clot dissolution, prevent hemorrhage generation again.Common drug is 6-aminocaprolc acid, Aminomethylbenzoic Acid, tranamic acid, also available reptilase, etamsylate, carbazochrome salicylate, tranamic acid, thromboplastinum and vitamin K1 etc.Clinical value is had to the Patients with Subarachnoid Hemorrhage going out blood coagulation disorders.
4. prevent and treat chronic cerebral vasospasm: delayed cerebral vasospasm is the main vital of aneurismal subarachnoid hemorrhage and one of the reason that disables, and mechanism is not clear, may be relevant with inflammatory reaction around brain vessel after subarachnoid hemorrhage.Routine should give nimodipine, to reduce the danger of vasospasm and cerebral infarction, should use as early as possible.Oral, or nasal feeding, every day 6 times, took once every 4 hours, each 60mg, as blood pressure falls be not too low, sustainablely use about 21 days.Its side effect has: flushing, headache and feel sick.
5. cerebrospinal fluid displacement therapy: cerebrospinal fluid is put in lumbar puncture, each slowly releasing 10 ~ 20mL, and slowly inject artificial cerebrospinal fluid, 2 times weekly, can intracranial pressure be reduced, alleviate headache, release blood and catabolite, reduce chronic cerebral vasospasm, normal pressure hydrocephalus incidence rate, should note bringing out cerebral hernia, intracranial infection and again bleeding risk, strictly grasp indication.
At present, the report that Chinese medicine is used for subarachnoid hemorrhage clinical treatment is little, comprising conventional western medicine treatment basis adds with red-rooted-salvia-root chuanxiong-rhizome azine injecta, the rheological characteristic of blood samples of patients can not only be improved, reduce the generation of sludged blood, and then improve the circulation etc. of cerebrospinal fluid, the incidence rate etc. of patient lungs's infection or other complication can not only be reduced, but also the rehabilitation of patient can be promoted; In addition, papaverine is used for delayed Cerebral Vasospasm After Subarachnoid Hemorrhage also has research report.
Summary of the invention
The object of this invention is to provide the application of a kind of Herba Hedyotidis Diffusae.
The object of the present invention is achieved like this: the application of this Herba Hedyotidis Diffusae, is characterized in that: Herba Hedyotidis Diffusae is as the application of preparation treatment subarachnoid hemorrhage medicine.
The concrete grammar of described application is select the injection of Herba Hedyotidis Diffusae or freeze dried powder with intravenous drip or intramuscular injection form administration; Minimum amount is adult patient according to BAIHUASHESHECAO ZHUSHEYE according to 2 ~ 4ml/ time, every day 2 times, Herba Hedyotidis Diffusae freeze dried powder 0.5mg ~ 1mg/ time, every day 2 times.
Described subarachnoid hemorrhage comprises the subarachnoid hemorrhage that congenital intracranial aneurysm and Sudden death cause, and also comprises abnormal vascular net disease at the bottom of hypertension, cerebral arteriosclerosis, intracranial tumor, hematopathy, brain (moya-moya is sick), subarachnoid hemorrhage that arteritis, encephalitis, anticoagulant therapy complication and meningitis bring out.
Application advantage of the present invention is:
(1) significantly alleviate the degree of cerebral edema that subarachnoid hemorrhage causes;
(2) promote the absorption of subarachnoid space remained blood;
(3) reduce the destructiveness of blood brain barrier;
(4) alleviate basilar artary vasospasm degree;
(5) improve Neuroscore etc.
By improving above-mentioned several clinical indices and then shielding to cerebral tissue, subarachnoid hemorrhage is had significant therapeutic effect.
The present invention is that the treatment of subarachnoid hemorrhage provides a new way, is described in further detail, but and does not mean that the present invention is only limitted to this below in conjunction with several specific embodiment to the present invention.
Accompanying drawing explanation
Fig. 1 is sham group (sham operated rats), SAH group, OD (2.5) treatment group (BAIHUASHESHECAO ZHUSHEYE 2.5ml/kg administration group) and OD (5) treatment group (BAIHUASHESHECAO ZHUSHEYE 5ml/kg administration group) four groups of degree of cerebral edema compare (mean+SD);
Fig. 2 is brain superficial hemorrhages amount subregion scoring exemplary plot;
Fig. 3 is sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group four groups of spinal subarachnoid space in rats remain blood volume and compare and mark;
Fig. 4 is sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group four groups of Neuroscore (mean+SD);
Fig. 5 sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group respectively organize Blood-Brain Barrier integrity and AZO-blue (EB) assay;
Fig. 6 is sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group respectively organize basilar artary vasospasm scale evaluation.
Detailed description of the invention
The experimental technique used in following embodiment if no special instructions, is conventional method.
Material used in following embodiment, reagent etc., if no special instructions, all can obtain from commercial channels.
The making of embodiment 1. Subarachnoid Hemorrhage in Rats model
We adopt internal carotid artery puncture method to set up rat sah model with reference to documents such as Bederson, and (animal model of subarachnoid hemorrhage adopted in the present embodiment is different from subarachnoid space note blood animal model, this kind of model is closer to clinical patients incidence), getting adult, healthy, body weight is the Sprague-Dawley(SD of 250-300g) rat, fixing with lying on the back after 10% chloral hydrate (3.5ml/kg) intraperitoneal injection of anesthesia.Fixing head and extremity, throat portion preserved skin, sterilization, get cervical region median incision, blunt separation exposes right carotid (common carotid artery, CCA), the ramus anastomoticus between ECA and ICA is cut off in external carotid artery (external carotidartery, ECA) and internal carotid artery (internal carotid artery, ICA) ligation, ECA ligation is cut off stretching, makes itself and ICA in line.Get 3-0 single stranded nylon line (diameter 0.261mm) by head end sharpening, mark in line end 20mm and 22mm place, nylon wire is inserted the intracranial segment of internal carotid artery from external carotid artery, insertion depth is about 20mm, and the 2mm that readvances when feeling there is resistance punctures blood vessel, causes subarachnoid hemorrhage, about 15 seconds rapid afterwards extracts nylon wire, with silk thread ligation external carotid artery stump, recover blood flow, sew up cervical incision.Body temperature 37 DEG C is maintained in art.Sham operated rats is not except puncturing except blood vessel wall, and all the other operations are all consistent with SAH group.Give electric blanket before anesthesia is not clear-headed warming, the single cage of postoperative rat is raised, and notes warming.BAIHUASHESHECAO ZHUSHEYE treatment group is 0.5h, 24h, 47h tail vein injection respectively after SAH, and inject 3 times altogether, injected dose is respectively 2.5ml/kg and 5ml/kg.All the other each group gives normal saline.
Embodiment 2. degree of cerebral edema detects
SD rat is divided into four groups at random, often organize 18, be respectively sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group, according to model preparation method in embodiment 1 and dosage regimen treatment, each group of rat 48h 10 % chloral hydrate anesthesia after SAH, open cranium and get full brain, cut full brain put into rapidly weigh up weight in advance tinfoil paper on weigh, this weight deducts tinfoil paper weight and is weight in wet base W1, put into subsequently after baking box dries 72h under 110 DEG C of conditions and again weigh, this weight deducts tinfoil paper weight and is dry weight W2, cerebral edema index and available following formula are tried to achieve.Cerebral edema index=[(W1-W2)/W1] × 100%.Experimental result such as Fig. 1 shows, and SAH group is compared with sham group, and brain water content exists significant difference, (* * * P<0.01); OD (2.5) group and OD (5) group compare with SAH group respectively, and brain water content all exists significant difference (###P<0.01).Illustrate that BAIHUASHESHECAO ZHUSHEYE significantly can alleviate the degree of subarachnoid hemorrhage associated with hydrocephalus.
After embodiment 3. subarachnoid hemorrhage, each group subarachnoid space remains blood volume measuring
SD rat is divided into four groups at random, often organize 18, be respectively sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group, according to model preparation method in embodiment 1 and dosage regimen treatment, each group of rat 48 h, 10 % chloral hydrate anesthesia after SAH, open cranium and get full brain.Take pictures with high resolution camera, to brain surface, each subregion amounts of bleeding such as Willis ring and basilar artery carry out observing (marking with reference to Fig. 2 example).Basement geology is divided into six parts (as Fig. 2 A), and each several part to divide from 0-3 according to amount of bleeding marks---and 0 point: cavity of resorption is not hemorrhage; 1 point: cavity of resorption has a small amount of blood; 2 points: the blood having moderate on the blood vessel that can distinguish; 3 points: on whole blood vessel, be covered with a large amount of blood (as Fig. 2 B and C).
Aortal grading system in Basement geology: the anterior cerebral artery (ACA) that basilar artery (BA) and Willis ring are formed, internal carotid artery (ICA), nearly rear end cerebral arteries (PCA) from ICA to posterior communicating artery and posterior communicating artery (PcomA) are marked.Middle cerebral artery (MCA), the non-tip of PCA and superior cerebellar artery (SCA) be not in the scope of scoring.Only mark to ensure repeatability and concordance to the blood vessel on Basement geology.
6 part overall scores of blood vessel assign to 18 points from 0.Final score according to animal is divided three classes: 0-7 divides: slight SAH; 8-12 divides: medium SAH; 13-18 divides: serious SAH.Experiment adopts double-blind method.Sham operated rats animal has no hemorrhage, must be divided into 0 point.
As shown in Figure 3, Fig. 3 A is that after modeling, 48h respectively organizes subarachnoid space and remains blood volume audio-visual picture to experimental result; Fig. 3 B is the appraisal result of each group of subarachnoid space blood volume: SAH group is compared with sham group, and subarachnoid space blood volume exists significant difference (* * * P<0.01); OD (2.5) group is compared with SAH group, and subarachnoid space blood volume significantly reduces, and there is significant difference (#P<0.01); OD (5) group compares with SAH group, and subarachnoid space blood volume significantly reduces, and also there is significant difference (###P<0.01).Illustrate that BAIHUASHESHECAO ZHUSHEYE can promote the absorption of remained blood after subarachnoid hemorrhage, thus reduce the correlated response bad to the stimulation of cerebral tissue and inflammation etc. such as hemoglobin.
Example 4. rat behavior-Neuroscore
SD rat is divided into four groups at random, often organizes 18, be respectively sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group, according to model preparation method in embodiment 1 and dosage regimen treatment.In postoperative 24h, behavioristics's Neuroscore is carried out to each treated animal with reference to Sugawara standard.Minimum point: 3 points, best result: 18 points.Score value is lower shows that the neurological deficit of animal is more serious.
(1) voluntary activity: rat is placed in cage and observes 5 minutes, marks according to the contact of cage wall.3 points: be free to motion, cage at least 3 side can be contacted; 2 points: cage sidewall can be touched, but less than 3 sides; 1 point: only can shift position; 0 point: can not move.
(2) quadruped locomotion is symmetrical: rat is carried the movement symmetry that tail is placed in its extremity of aerial observation.3 points: extremity are symmetrical, with no significant difference before arachnoid hemorrhage; 2 points: limb adynamia or bradykinesia; 1 point: limbs are extremely unable, only have light activity; 0 point: limbs can not move.
(3) forward foot in a step is stretched: rat is carried the edge of tail to desk, allow its forward limb move ahead, and observation is when the stretching, extension situation close to forelimb during desktop.3 points: two forelimb extensions is with before subarachnoid hemorrhage; 2 points: foreleg stretches calibration constant; 1 point: foreleg only has slight stretching, extension; 0 point: foreleg attonity.
(4) climb: be placed in by rat on vertical 10cm × 100cm wire netting, time normal, rat extremity swash, and carry tail and make rat leave cage, observation rat limb force.3 points: creep easily, keep a firm hand on wire netting strong; 2 points: climbing difficulty; 1 point: can not climb.
(5) touching of bilateral trunk is reacted: with blunt nosed wooden stick stimulation in rats side health, observe it to the reaction stimulated.3 points: the rapid rotary head of rat, Bilateral Symmetry; 2 points: only have slight reaction; 1 point: reactionless to the touching of trunk.
(6) antenna reaction: blunt nosed wooden stick stimulates side beard, and wooden stick touches beard from behind and avoids rat to see wooden stick.3 points: Bilateral Symmetry reacts; 2 points: minor response; 1 point: reactionless.
As shown in Figure 4, SAH group is compared with sham, and behavioristics's Neuroscore exists significant difference (* * * P<0.01) for result; OD (2.5) group and OD (5) group compare with SAH group respectively, and neurological deficit score is significantly increased, and there is significant difference (###P<0.01).Illustrate that BAIHUASHESHECAO ZHUSHEYE can significantly improve the behavioral competence of animal after subarachnoid hemorrhage, reduce the damage of function of nervous system.
Example 5. blood-brain barrier permeability measures
SD rat is divided into four groups at random, often organizes 18, be respectively sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group, according to model preparation method in embodiment 1 and dosage regimen treatment.Then according to the following step, blood-brain barrier permeability is detected:
(1) Criterion curve: preparing 0.1 mg/ml EB solution is initial concentration liquid, carry out doubling dilution, form the EB normal concentration of gradient solution 0.1,0.05,0.025,0.0125,0.0063, application UV detector 620nm carries out colorimetric, formamide solution does blank, carries out regression analysis and tries to achieve standard curve.
(2) after rat anesthesia through vena femoralis injection 2% EB (5 ml/kg), put to death after 1h, for removing dyestuff in blood, ventricles normal saline is till right ventricle flows out transparency liquid left, brain is got after broken end, be divided into left brain, right brain and cerebellum three parts, immerse in formamide solution by 10ml/g after weighing, extracting 24h in 60 DEG C of constant water bath box, formamide solution presents the different blueness of the depth, cerebral tissue presents water white transparency shape, then applies UV detector and carries out colorimetric, wavelength setting 620nm.EB content is calculated according to standard curve.
As shown in Figure 5, in L.H (left half brain), R.H (right half brain) and C (cerebellum) three Different brain region, SAH group is compared with sham group, and in cerebral tissue, EB content is significantly higher than sham group (* P<0.01); OD (2.5) group and OD (5) group compare with SAH group respectively, and in cerebral tissue, EB content is significantly lower than SAH group (#P<0.01).These experimental datas show, and BAIHUASHESHECAO ZHUSHEYE significantly can reduce the destructiveness of blood brain barrier, improve the integrity of blood brain barrier, play a protective role to cerebral tissue.
The angiospastic detection of example 6. rat brain
SD rat is divided into four groups at random, often organizes 18, be respectively sham group, SAH group, OD (2.5) treatment group and OD (5) treatment group, according to model preparation method in embodiment 1 and dosage regimen treatment.Test according to following method:
One, draw materials: experimental rat opens breast through left side, cut off pericardium and expose heart, on diaphram, thoracic cavity inner clip closes thoracic aorta and postcava, puncture in apex of the heart place with 27G remaining needle, and remaining needle is put ascending aorta, then right auricle is cut off, first with the normal saline flushing containing heparin (20 U/ml), measure about 150-200ml, get rid of vessel inner blood, then and with 4% paraformaldehyde heart perfusion, speed first quick and back slow, infusion time is about 10min ~ 15min, measure about 250-300ml, can find in this process, rat neck is hardening gradually, the two upper limb of rat or tic of the limbs.After perfusion terminates, open cranium and get brain, observe hematocele situation around brain Basement geology and Willis arterial ring, then tissue specimen is soaked in 4% paraformaldehyde and spends the night.
Two, HE dyeing: the gross morphology structure of main display basilar artery.
Staining procedure is as follows:
(1) paraffin section enters each 10 min of dimethylbenzene I, II dewaxing;
(2) each 3 min of dehydrated alcohol I, II, each 5s of graded ethanol 95%, 90%, 85%, 80%, 70%, distillation washing;
(3) haematoxylin dyeing 4 min;
(4) 1% hydrochloride alcohol color separation 2s, basis of microscopic observation grasps color separation degree;
(5) 20min is washed from the beginning, oil blackeite;
(5) eosin stains liquid is immersed (0.5%) 1 minute;
(8) each 1min of graded ethanol 90%, 95%, each 5min of dehydrated alcohol I, II;
(9) the transparent each 5min of dimethylbenzene I, II;
(10) neutral gum mounting.
Three, measure: get every Rat Basilar HE stained, take pictures under Nikon optical microscope, reference literature method [3] is by measuring basilar artery Lumen Area determination vasospasm degree.Adopt Image Pro Plus image analysis system computer tube cavity area and gross area ratio, finally apply SPSS 17.0 and carry out statistical analysis.
Experimental result as shown in Figure 6, Fig. 6 A: each group basilar artery metamorphosis (HE, 200); Fig. 6 B: each group vasospasm degree statistical: 2 days and 7 days SAH groups compare with sham group, vasospasm degree all increases, and there is significant difference (* P<0.01); OD (2.5) group and OD (5) group compare with SAH group respectively, and vasospasm degree is all remarkable in SAH group (###P<0.01).Experimental result illustrates, BAIHUASHESHECAO ZHUSHEYE effectively can prevent the angiospastic generation of basilar artary.
In sum, the present invention is confirmed by a large amount of animal experiment in vivo, and Herba Hedyotidis Diffusae has definite therapeutic effect in the treatment of the brain injury of subarachnoid hemorrhage.
Claims (3)
1. an application for Herba Hedyotidis Diffusae, is characterized in that: Herba Hedyotidis Diffusae is as the application of sole active composition at preparation treatment subarachnoid hemorrhage medicine.
2. the application of Herba Hedyotidis Diffusae according to claim 1, is characterized in that: the concrete grammar of described application is select the injection of Herba Hedyotidis Diffusae or freeze dried powder with intravenous drip or intramuscular injection form administration; Minimum amount is adult patient according to BAIHUASHESHECAO ZHUSHEYE according to 2 ~ 4ml/ time, every day 2 times, Herba Hedyotidis Diffusae freeze dried powder 0.5mg ~ 1mg/ time, every day 2 times.
3. the application of the Herba Hedyotidis Diffusae described in claim 1 or 2, it is characterized in that: described subarachnoid hemorrhage is the subarachnoid hemorrhage that congenital intracranial aneurysm and Sudden death cause, the subarachnoid hemorrhage that at the bottom of hypertension, cerebral arteriosclerosis, intracranial tumor, hematopathy, brain, abnormal vascular net disease, arteritis, encephalitis, anticoagulant therapy complication and meningitis bring out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410155195.7A CN103893325B (en) | 2014-04-18 | 2014-04-18 | The application of Herba Hedyotidis Diffusae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410155195.7A CN103893325B (en) | 2014-04-18 | 2014-04-18 | The application of Herba Hedyotidis Diffusae |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103893325A CN103893325A (en) | 2014-07-02 |
| CN103893325B true CN103893325B (en) | 2015-11-04 |
Family
ID=50985111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410155195.7A Active CN103893325B (en) | 2014-04-18 | 2014-04-18 | The application of Herba Hedyotidis Diffusae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893325B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106668054B (en) * | 2017-01-18 | 2019-03-22 | 中国人民解放军北部战区总医院 | The application of isovincoside lactone |
| CN112569219B (en) * | 2019-09-30 | 2023-05-02 | 中国科学院上海药物研究所 | Medicine for treating artery related diseases and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129521A (en) * | 2007-09-11 | 2008-02-27 | 浙江大学 | Effective component of hedyotis diffusa and method of preparing the same and application |
| CN101574420A (en) * | 2008-05-09 | 2009-11-11 | 中国科学院上海生命科学研究院 | Application of oldenlandia diffusa acting on retinol X receptor |
| CN101654485A (en) * | 2009-09-04 | 2010-02-24 | 山东中医药大学附属医院 | Spreading hedvotis herb polysaccharide for curing malignant tumor and preparation method thereof |
-
2014
- 2014-04-18 CN CN201410155195.7A patent/CN103893325B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129521A (en) * | 2007-09-11 | 2008-02-27 | 浙江大学 | Effective component of hedyotis diffusa and method of preparing the same and application |
| CN101574420A (en) * | 2008-05-09 | 2009-11-11 | 中国科学院上海生命科学研究院 | Application of oldenlandia diffusa acting on retinol X receptor |
| CN101654485A (en) * | 2009-09-04 | 2010-02-24 | 山东中医药大学附属医院 | Spreading hedvotis herb polysaccharide for curing malignant tumor and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 浅析中风病恢复期的病机与治疗;赵骥;《山西中医》;20080531;第24卷(第5期);第59-60页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103893325A (en) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lv et al. | Hydroxysafflor yellow A exerts neuroprotective effects in cerebral ischemia reperfusion-injured mice by suppressing the innate immune TLR4-inducing pathway | |
| CN102861287B (en) | Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof | |
| CN103893325B (en) | The application of Herba Hedyotidis Diffusae | |
| US9956265B2 (en) | Composition for aiding surgical procedures for treating ischemic vascular diseases | |
| Penner et al. | Studies in the Pathogenesis of Experimental Dysentery Intoxication: Production of Lesions by Introduction of Toxin Into the Cerebral Ventricles | |
| JP2014526518A (en) | Compounds and methods for treating heart failure or neuronal damage | |
| CN106668348A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| CN103417522A (en) | Applications of L-serine in preparing medicines used for treating brain injuries and nerve tissue injuries | |
| WO2022170940A1 (en) | Cell-free fat extract for use in improving aging and promoting skin rejuvenation | |
| CN106668054B (en) | The application of isovincoside lactone | |
| US20210154217A1 (en) | Polydextrose for the prevention and/or treatment of heart failure | |
| CN102327359B (en) | Compound nifedipine ointment and application thereof | |
| CN105287755A (en) | Traditional Chinese medicinal composition for treating sepsis myocardial dysfunction | |
| CN101167733A (en) | Venous injection powder injection for preventing and treating ischemic cerebral apoplexy and preparation method thereof | |
| CN104906294A (en) | Traditional Chinese medicine combination for treating senile dementia and detection method thereof | |
| CN101019905B (en) | Medicine composition containing tribulus fruit furostanol saponin and application thereof | |
| CN102784223A (en) | Application of three-medicine ointment in preparation of drugs used for preventing and curing phlebitis | |
| CN116492360B (en) | Application of trefoil glycoside and related products | |
| CN113980068B (en) | Geraniin and application thereof in preparation of medicines for preventing and treating cerebral ischemia reperfusion injury | |
| CN113967220B (en) | Pharmaceutically active composition with acute myocardial infarction curative effect | |
| CN1272036C (en) | Medicinal injection for treating cardio-cerebrovascular disease and preparing method thereof | |
| CN108339008A (en) | A kind of application of the pellet phenol preparation in anti-cerebral ischemia reperfusion injury drug | |
| CN103908661A (en) | Application of human albumin in preparing drug for treating subarachnoid hemorrhage | |
| CN101269062A (en) | Application of loganin in preparing medicament for treating cardiovascular and cerebrovascular diseases | |
| CN109223815A (en) | A kind of purposes of pharmaceutical composition in preparation treatment acetyl cholinergic urticaria drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190225 Address after: 110016 No. 87 Cultural Road, Shenhe District, Shenyang City, Liaoning Province Patentee after: General Hospital of the Northern War Zone of the Chinese People's Liberation Army Address before: 110016 No. 87 Cultural Road, Shenhe District, Shenyang City, Liaoning Province Patentee before: Li Xiaoming |
|
| TR01 | Transfer of patent right |